Idogen (publbl) announced that the organization has been strengthened with several leang key roles before the companany's most advanced drug candidate enters the clinical development phase. The management team is thus expanded with competence and experience in both early drug development and clinical trials. In March 2022, Idogen received approval from the Medical Products Agency to initiate a clinical phase 1/2a study in the development program IDO
8, a potentially revolutionary cell therapy for patients with severe hemophilia A who have developed antibodies to their vital treatment with coagulation factor VIII. The study will be conducted at several testing centers in Europe and before the start, the company is now strengthening the organization with three new employees.